Literature DB >> 2390430

Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule.

S Harder1, U Fuhr, D Beermann, A H Staib.   

Abstract

1. The absorption of ciprofloxacin from different regions of the human gastrointestinal tract was investigated in four healthy males using a remote-controlled drug delivery device (hf-capsule). 2. Significant differences in AUC were observed in the control study (oral administration of ciprofloxacin solution without the hf-capsule = 100%) and after release of ciprofloxacin in the jejunum (geometric mean: 37%), the ileum (mean: 23%), the ascending colon (mean: 7%) and the descending colon (mean: 5%), whereas tmax showed no difference for any of the absorption sites. Ciprofloxacin release in the stomach resulted in the greatest AUC (mean: 140%). Thus, it is concluded that the main absorption site of ciprofloxacin is the upper gastrointestinal tract, up to the jejunum. 3. Differences in presystemic metabolism of known drug metabolites along the gut could be excluded, as the pattern of urinary recovery of desethylene-, sulpho-, and oxo-ciprofloxacin and the parent compound was similar for all drug release sites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2390430      PMCID: PMC1368272          DOI: 10.1111/j.1365-2125.1990.tb03740.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Measurement of theophylline absorption from different regions of the gastro-intestinal tract using a remote controlled drug delivery device.

Authors:  A H Staib; D Loew; S Harder; E H Graul; R Pfab
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Sensitive and selective determination of picogram amounts of ciprofloxacin and its metabolites in biological samples using high-performance liquid chromatography and photothermal post-column derivatization.

Authors:  H Scholl; K Schmidt; B Weber
Journal:  J Chromatogr       Date:  1987-05-15

Review 3.  The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics.

Authors:  D E Nix; J J Schentag
Journal:  J Clin Pharmacol       Date:  1988-02       Impact factor: 3.126

Review 4.  Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

Review 5.  Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Authors:  M Neuman
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

6.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

7.  Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses.

Authors:  T Bergan; S B Thorsteinsson; R Solberg; L Bjornskau; I M Kolstad; S Johnsen
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

  7 in total
  14 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions.

Authors:  Emilie Hénin; Martin Bergstrand; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2015-11-09       Impact factor: 4.200

3.  Clinical Equivalency of Ciprofloxacin 750 mg Enterally and 400 mg Intravenously for Patients Receiving Enteral Feeding: Systematic Review.

Authors:  Donna Chui; Lily Cheng; Aaron M Tejani
Journal:  Can J Hosp Pharm       Date:  2009-03

4.  Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women.

Authors:  Jean L Fourcroy; Bret Berner; Yu-Kun Chiang; Marilou Cramer; Lynne Rowe; Neal Shore
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Evaluation of the feasibility and use of a prototype remote drug delivery capsule (RDDC) for non-invasive regional drug absorption studies in the GI tract of man and beagle dog.

Authors:  A F Parr; E P Sandefer; P Wissel; M McCartney; C McClain; U Y Ryo; G A Digenis
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

6.  Absorption of ofloxacin isomers in the rat small intestine.

Authors:  L Rabbaa; S Dautrey; N Colas-Linhart; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

7.  Absorption of ipsapirone along the human gastrointestinal tract.

Authors:  U Fuhr; A H Staib; S Harder; K Becker; D Liermann; G Schöllnhammer; I S Roed
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

Review 8.  Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option.

Authors:  Joseph M Blondeau
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Use of Modeling and Simulation Tools for Understanding the Impact of Formulation on the Absorption of a Low Solubility Compound: Ciprofloxacin.

Authors:  Marilyn Martinez; Bipin Mistry; Viera Lukacova; Jim Polli; Stephen Hoag; Thomas Dowling; Ravikanth Kona; Raafat Fahmy
Journal:  AAPS J       Date:  2016-04-26       Impact factor: 4.009

10.  A case study of in silico modelling of ciprofloxacin hydrochloride/metallic compound interactions.

Authors:  Aleksandra Stojkovic; Jelena Parojcic; Zorica Djuric; Owen I Corrigan
Journal:  AAPS PharmSciTech       Date:  2013-12-05       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.